A comparison of COPD patients with and without ACOS in the ECLIPSE study

European Respiratory Journal

Volumn 47, Issue 5, 2016, Pages 1559-1562

  Wurst, Keele E ^a   Rheault, Tara R ^a   Edwards, Lisa ^a,b   Tal Singer, Ruth ^a   Agusti, Alvar ^c   Vestbo, Jørgen ^d  

^a GLAXOSMITHKLINE   (United States)

^b PAREXEL INTERNATIONAL   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AGE; ASTHMA; ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME; ATOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DRUG USE; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; SEX RATIO; SMOKING; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOM; WHEEZING; COMPLICATION; CONNECTIVE TISSUE DISEASE;

ASTHMA; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNDIFFERENTIATED CONNECTIVE TISSUE DISEASES;

EID: 84969837251     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02045-2015     Document Type: Letter

References (13)

1. Bateman ED, Reddel HK, van Zyl-Smit RN, et al. The asthma-COPD overlap syndrome: Towards a revised taxonomy of chronic airways diseases? Lancet Respir Med 2015; 3: 719-728.
2. Postma DS, Rabe KF. The Asthma-COPD overlap syndrome. N Engl J Med 2015; 373: 1241-1249.
3. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008; 31: 869-873.
4. Ferris BG. Epidemiologhy Standardizaton Project (American Thoracic Society). Am Rev Respir Dis 1978; 118: 1-120.
5. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS One 2012; 7: e37483.
6. Shaya FT, Dongyi D, Akazawa MO, et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest 2008; 134: 14-19.
7. Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011; 12: 127.
8. Hardin M, Cho M, McDonald ML, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 2014; 44: 341-350.
9. Menezes AM, Montes de Oca M, Perez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014; 145: 297-304.
10. Iwamoto H, Gao J, Koskela J, et al. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J 2014; 43: 421-429.
11. Diaz-Guzman E, Khosravi M, Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. COPD 2011; 8: 400-407.
12. Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 2012; 7: 283-289.
13. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012; 67: 701-708.